Related Experiment Video
Updated: Sep 21, 2026
Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice
Published on: April 14, 2011
[Clinical study of SM-4300 in infectious diseases of pediatrics]
Insights
SM-4300, an immunoglobulin preparation, showed a 60% efficacy rate in treating severe pediatric infectious diseases when used with antibiotics. This treatment demonstrated no significant side effects in clinical trials.
Area of Science:
- Immunology
- Pediatric Infectious Diseases
Background:
- Severe pediatric infections pose significant health challenges.
- Intravenous immunoglobulin preparations are used to manage various conditions.
- SM-4300 is a novel immunoglobulin preparation developed using ion-exchange treatment.
Observation:
- The study evaluated SM-4300 in 12 pediatric cases (under 10 years) with diverse infectious diseases including sepsis, pneumonia, and meningitis.
- Two cases were excluded from efficacy evaluation due to immediate death or blood transfusion.
- Concomitant antibiotic therapy complicated direct efficacy assessment of SM-4300.
Findings:
- Among 10 evaluated cases, 2 showed excellent effectiveness and 4 showed fair effectiveness, resulting in a 60% overall efficacy rate when including fairly effective cases.
- No significant adverse clinical or laboratory side effects were observed during the study.
- SM-4300 was well-tolerated in the pediatric population studied.
Implications:
- SM-4300 shows potential as an adjunctive therapy for severe pediatric infectious diseases, particularly when used alongside antibiotics.
- Further research is warranted to fully elucidate the efficacy and optimal use of SM-4300 in pediatric infectious disease management.
- The safety profile suggests SM-4300 could be a valuable therapeutic option in critical care settings for children.
Abstract:
SM-4300, a new developed immunoglobulin preparation with ion-exchange treatment, was used intravenously for 12 infectious diseases. These 12 cases (under 10 years old) were including 4 sepsises, 3 pneumonias, 1 pyothorax, 1 ventriculitis, 1 purulent meningitis, 1 aseptic meningitis and 1 cellulitis. To evaluate the effect of SM-4300, 2 cases were excluded from evaluation because of blood transfusion or immediately death. Since antibiotics were used at the same time, it was surely difficult to evaluate the effect of SM-4300. In 10 cases, 2 cases were excellent effective, 4 cases were fairly effective and others were not effective. Including fairly effective cases, the rate of efficacy was 60%. In all cases, there were no significant side effects regarding clinical findings and laboratory examinations. SM-4300 may be available for severe infectious diseases with antibiotics therapy.
More Related Videos
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022